Doctors have a clear first choice for treating chronic insomnia, and it isn’t a pill.
Quick Take
- Major medical guidelines now name cognitive behavioral therapy for insomnia, or CBT-I, as the first treatment doctors should try for chronic insomnia.
- Guidelines say sleep medications should mostly be a backup, used when therapy isn’t available or doesn’t fully work.
- Despite the guidance, most patients still end up on pills because CBT-I therapists are hard to find.
- Common sleep drugs carry real side effects, including dizziness, next-day grogginess, and dependence risk.
What The Guidelines Actually Say
The American College of Physicians told doctors in 2016 to use CBT-I as the starting treatment for chronic insomnia, not medication. The European Insomnia Guideline updated that stance in 2023, saying CBT-I should be first-line “for insomnia disorder in adults of any age, regardless of comorbidities.” The American Academy of Sleep Medicine backs the same order of operations.
None of these groups dismiss medication outright. They simply rank it second. The Australasian Sleep Association calls CBT-I “universally accepted as the best treatment modality for insomnia disorder, in the long term” and says it “remains the gold standard of treatment.” That’s a strong, repeated signal across continents and medical societies, not a single outlier opinion.
Why Behavioral Therapy Beats A Pill Long-Term
CBT-I works by retraining sleep habits and thought patterns, not by sedating the brain. The American Academy of Family Physicians says it improves “quality of sleep, insomnia severity, daytime fatigue, total sleep time, and beliefs and attitudes about sleep.” That’s a broader win than most sleep drugs claim, and the benefits tend to stick around after treatment ends, unlike a pill’s effect, which fades once you stop taking it.
The sleep medicine group’s pharmacology guideline puts it plainly: medications should mainly be considered when patients can’t do CBT-I, don’t respond to it, or need something temporary while therapy takes hold. That’s a narrower role than how sleep drugs are often marketed and used in everyday practice.
The Gap Between Guidelines And Real Prescriptions
Here’s the catch. Even though CBT-I is called the gold standard, most people with insomnia never get it. Research on treatment barriers points to a shortage of trained CBT-I therapists, doctors who don’t screen for sleep problems, and limited insurance coverage for behavioral sessions. One sleep journal summary flatly states CBT-I “remains massively underused relative to the prevalence of insomnia disorder.”
That access gap explains why prescription data still shows heavy use of sleep drugs. Trazodone and zolpidem top national prescribing charts, with trazodone prescribed at more than 130 per 1,000 enrollees in recent tracking. Doctors reach for what’s available and fast, even when guidelines point elsewhere. That’s not malpractice — it’s a system with too few therapists and too many patients who can’t wait months for an appointment.
What The Risk Side Looks Like
Sleep medications aren’t dangerous for everyone, but they aren’t risk-free either. A recent network analysis found drugs like zolpidem, zopiclone, and eszopiclone carry higher rates of dizziness, headache, nausea, and daytime drowsiness compared with other options. Older adults face extra concern around falls and next-day impairment, a point sleep specialists raise often when discussing benzodiazepines and Z-drugs with patients.
Digital and telehealth versions of CBT-I now offer a workaround for the access problem. Recent evidence reviews say online CBT-I programs perform close to in-person therapy, making them a practical first-line option when a local therapist isn’t available. For readers frustrated by sleepless nights, that’s a real, actionable alternative to defaulting straight to a prescription pad.
The Bottom Line For Patients
The clinical consensus is not ambiguous: try structured behavioral therapy before reaching for a nightly pill. Guidelines from multiple countries and professional bodies agree on this order, even while acknowledging medication has a legitimate, narrower role. The real obstacle isn’t disagreement among doctors — it’s getting patients connected to the therapy that guidelines already say works best.
Sources:
onlinelibrary.wiley.com, healio.com
